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Rapport de synthèse 
EVALUATION DE MARQUEURS P ARACLINIQUES DE 
L'ATHEROSCLEROSE CHEZ DES SUJETS SOUFFRANT D'UN EXCES 
PONDERAL ET D'UNE DYSLIPIDEMIE. «Surrogate Markers for 
Atherosclerosis in Overweight Subjects With Atherogenic Dyslipidemia: The 
GEMS Project (peer-reviewed)» Angiology 2008 Aug-Sep;59(4):484-92. 
Myriam Genoud, Vincent Wietlisbach, François Feihl, Alice Me1mod, Diane Morin, Roger 
Darioli, Pascal Nicod, Vincent Mooser, Bernard Waeber, Daniel Hayoz, etGérard Waeber 
Le syndrome métabolique (défini par les critères ATP III par la présence au minimum de 3 
des facteurs suivants: taux plasmatiques d'HDL-cholestérol < 1,04 mmol/l chez l'homme et 
< 1.29 mmol/l chez la femme, taux plasmatiques de triglycérides> 1,69 mmol/l, tension 
artérielle~ 130/85 mmHg, glycémie~ 6,1 mmol/l, tour de taille> 108 cm chez l'homme et 
> 88 cm chez la femme) représente une constellation de facteurs de risque majeurs pour le 
développement de maladies cardiovasculaires. Il n'est pas encore établi actuellement quelle 
composante de ce syndrome contribue de manière plus marquée au risque de développer une 
athérosclérose. Dans le but d'éclaircir la pathogenèse de ce syndrome, une étude 
multicentrique intitulée GEMS («Genetie Epidemiology of Metabolic Syndrome») a été 
initiée afin de déterminer si la constellation d'une dyslipidémie avec HDL-C bas et TG élevé 
est un marqueur sensible de l'homogénéité génétique chez les individus atteints de syndrome 
métabolique. 
Dans l'étude menée à Lausaime (multicentrique), la contribution de la dyslipidémie avec 
HDL-C bas et TG élevé dans la pathogenèse de l'athérosclérose a été évaluée par 2 examens, 
reconnus comme marqueurs fiables de la vasculopathie : la mesure de l'épaisseur intima 
média carotidienne par ultrasonographie et l'évaluation de la dysfonction endothéliale de la 
microcirculation cutanée. Deux groupes de sujets comparables en tern1e d'âge et de sexe et 
souffrant d'un excès pondéral (BMI > 25 kg/m2) mais normoglycémiques ont été comparés. 
Ces deux groupes (étude cas-témoins) étaient uniquement discordants quant à leurs profils 
lipidiques. Ainsi, 120 cas, définis comme ayant un HDL-cholestérol bas (:: 25 percentile pour 
l'âge et le sexe dans la population générale) et des TG élevés(~ 75 percentile) ont été 
comparés à 120 contrôles avec un HDL-cholestérol haut(~ 50 percentile) et des TG bas 
(:S 50 percentile ). Un doppler des artères carotides et fémorales a été effectué pour déterminer 
l'épaisseur de l'intima média et la présence ou non de plaques d'athérome. La fonction 
endothéliale a été évaluée par un laser doppler sur la micro-circulation cutanée (réponse 
hyperémique à une occlusion transitoire de la circulation de l'avant-bras par une manchette à 
pression et mesure de la vasodilatation induite par un échauffement local de la peau avec de 
l'eau). Un enregistrement de la pression artérielle ambulatoire sur la journée (Remler) a été 
pratiqué chez tous les sujets. 
Les résultats obtenus montrent que les cas ont une prévalence plus élevée de plaques 
d'athérome (médiane 1,5 ± 0,15 vs 0,8 ~ 0,15, p<.001), une épaisseur intima média plus 
importante (médiane 0,66 ± 0,15 vs 0,61±0,15, p<.01), ainsi qu'une réduction significative 
de la vasodilatation endothéliale induite par la chaleur et post-ischémique comparativement 
aux contrôles. 
En conclusion, le profil lipidique associant un HDL-cholestérol bas et des triglycérides élevés 
représente un risque majeur de développer une maladie athéromateuse périphérique et est 
associée à une augmentation de l'épaisseur intima média et une altération de la fonction 
endothéliale chez les individus en surcharge pondérale. Bien qu'un HDL-cholestérol bas soit 
fréquemment associé à une hypertriglycéridémie, les résultats de notre étude peuvent suggérer 
un rôle potentiel de la fraction HDL-cholestérol comme un puissant agent anti-athérogénique. 
EVALUATION DE L'INSULINO- SECRETION INDUITE PAR LE 
GLUCOSE CHEZ DES SUJETS EUGLYCEMIQUES SOUFFRANT D'UNE 
DYSLIPIDEMIE OU NON. « Glucose-Induced Insulin Secretion in 
Dyslipidemic and Normolipidemic Patients With Normal Glucose Tolerance » 
Diabetes Care, volume 28, number 5, pp. 1225-7, May 2005 
Christophe Binnert, Myriam Genoud, Gérald Seematter, Assia Fekirini, Vincent Mooser, 
Gérard Waeber, Luc Tappy 
Le syndrome métabolique est très prévalent dans les pays industrialisés, où il représente un 
enjeu majeur de santé publique en raison des risques de survenue de maladies 
cardiovasculaires et de diabète. La constellation d'un taux bas d'HDL-cholestérol et d'un taux 
élevé de triglycérides est un important constituant de ce syndrome. Le but de cette étude fut 
d'évaluer si l'altération du profil lipidique observée dans le syndrome métabolique est 
associée à une altération de la sécrétion ou de la sensibilité à l'insuline chez les sujets avec un 
test de tolérance au glucose normal. 
L'homéostasie glucidique a été évaluée par un clamp hyperglycémique dans un groupe de 
sujets dyslipidémiques et un groupe de sujets normolipidémiques comparables pour l'âge et le 
BMI, après l'administration de dexaméthasone durant 2 jours (procédure appliquée dans le 
but de diminuer la sensibilité à l'insuline avec une hyperinsulinémie compensatrice). Les 
résultats obtenus démontrent que les sujets dyslipidémiques ont une sécrétion augmentée 
d'insuline induite par le glucose afin de compenser l'altération de la sensibilité à l'insuline. 
L'administration sur une courte période de dexaméthasone peut détecter une résistance à 
l'insuline sub-clinique chez les sujets dyslipidémiques. Deux hypothèses ont été émises : la 
première est que l'hyperinsulinémie chronique consécutive à la résistance à l'insuline pourrait 
contribuer à une augmentation des TG plasmatiques par une stimulation de la lipogenèse 
hépatique de novo et une sécrétion des lipoprotéines VLDL. La deuxième hypothèse serait 
que l'altération primaire du métabolisme lipidique hépatique pourrait au long court contribuer 
au développement de la résistance à l'insuline et de l'hyperinsulinémie. Seules des études 
prospectives chez des individus à risque de développer un syndrome métabolique pourraient 
apporter des clarifications sur ces 2 hypothèses. 
Mesure de la pression artérielle ambulatoire: une approche pour quantifier le 
risqué cardiovasculaire« Ambulatory blood pressure monitoring: a mean to 
stratify cardiovascular risk » 
Blood Press Monit. 2007 Aug ,'12(4) :243-4 
Waeber B, Genoud M, Feihl F, Hayoz D, Waeber G 
Les recommandations actuelles pour la prise en charge de l'hypertension artérielle insistent 
sur l'importance d'une évaluation complète des facteurs de risque cardiovasculaires mais 
n'incluent pas la contribution de l'enregistrement de la pression artérielle en ambulatoire 
(Remler) dans la stratification du risque cardio-vasculaire. 
Dans cette étude, nous avons calculé le risque cardiovasculaire global selon les 
recommandations 2003 de la Société Européenne d'hypertension et la Société Européenne de 
cardiologie chez 127 sujets chez lesquels un enregistrement de la pression artérielle sur 12 
heures (le jour) a été effectué, ainsi que la réalisation d'un doppler artériel carotidien et 
fémoral. 
Les résultats démontrent que l'enregistrement d'une pression aiiérielle ~ 135/85 mmHg 
déplace le risque cardio-vasculaire à un plus haut niveau, de même que la présence d'une 
hypercholestérolémie et encore plus la détection de plaques d'athérome au doppler. 
D'autres études sont encore requises pour déterminer définitivement le rôle de 
l'enregistrement de la pression artérielle en ambulatoire (Remler) dans l'évaluation du risque 
cardio-vasculaire. 
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Myriam Genoud, Vincent Wietlisbach, François Feihl, Alice Mermod, 
Diane Morin, Roger Darioli, Pascal Nicod, Vincent Mooser, Bernard Waeber, 
Daniel Hayoz, and Gérard Waeber 
Metabolic syndrome is a constellation of major risk fac-
tors for cardiovascular disease. In affected individuals 
with this syndrome, the independent contribution of 
low high-density lipoprotein-cholesterol and increased 
triglyceride levels to the development of atherosclero-
sis remains to be clarified. V.Te assessed the relation-
ship between these 2 parameters and several surrogate 
mark.ers for atherosclerosis. One hundred and twenty 
overweight cases, defined as having high-density 
lipoprotein-cholesterol (s2 5 age- and gender-specific 
percentile in general population) and high triglyceride 
values (?75 percentile) were compared with 120 discordant 
overweight controls defined on lipid values (high-density 
lipoprotein-cholesterol ?50 percentile and triglycerides 
s50 percentile). Case-control pairs were matched for age 
and gender. Carotid and femoral arteries were examined 
T he age-ajusted prevalence of metabolic syndrome as defined by Adult Treatment Program-III (ATPIII) in the United States is approximately 
24%. 1 The ATPIII definition includes at least 3 of the fol-
lowing abnormalities: waist circumference greater than 
102 cm in men and 88 cm in women; serum triglyceride 
levels of at least 1.69 mmol/L; high-density lipoprotein 
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to determine carotid intima-media thickness and the 
presence of atherosclerotic plaque(s). Endothelial fonc-
tion was assessed by laser Doppler flowmetry in the skin 
microvasculature. Daytime ambulat01y blood pressure 
monitoring was performed for each subject. Cases had 
higher prevalence of atherosclerotic plaques (mean 1.50 
± 0.15 vs 0.80 ± 0.15, P < .001), increased carotid 
intima-media thiclmess (mean 0.66 ± 0.15 vs 0.61 ± 
0.15, P < .01), and a significantly reduced temperature-
induced and postischemic endothelial vasodilation com-
pared with controls. ln conclusion, low high-density 
lipoprotein-cholesterol and high triglycerides levels are 
major contributors to peripheral atherosclerosis and are 
associated with an increase in intima-media thiclmess 
and impaired microvascular endothelial fonction in over-
weight individuals. 
(HDL)-cholesterol ofless than 1.04 mmol/L in men and 
1.29 mmol/L in women; blood pressure of at least 
130/85 mm Hg; and serum glucose of at least 6.1 
mmol/L. 2 High-normal levels of C-reactive protein 
are also common in individuals with metabolic syn-
drome, thereby leading one to consider the presence 
of a low-grade chronic inflammation as one compo-
nent of the metabolic syndrome. 3•4 The clustering of 
these metabolic components is associated with a 
markedly increased risk for cardiovascular disease. 2 
Coronary heart disease, peripheral artery disease, 
and stroke are the main clinical manifestations of 
generalized atherosclerosis. Independently, high 
blood pressure, dyslipidemia, and diabetes are estab-
lished risk factors for developing atherosclerosis. l,s-s 
However, in the context of multiple metabolic 
abnormalities, it is not yet established which com-
ponent(s) of the metabolic syndrome is(are) the 
major contributor(s) to atherogenesis. 
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Since the clinical manifestations of atheroscle-
rosis may be apparent only decades after the initia-
tion of the disease process, there has been an 
intensive search for surrogate markers of atheroscle-
rosis. ln order to be useful, these markers have to be 
easily measurable and should correlate with the clini-
cal manifestations of atherosclerosis. The determina-
tion of the carotid intima-media thiclmess (IMT) has 
been established and validated as a surrogate marker 
of cardiosvascular risk. This parameter can be meas-
ured noninvasively by ultrasonography and provides a 
quantitative evaluation of morphological changes in 
large arteries. 9' 10 Endothelial dysfunction has also 
been shown to occur early during the development of 
atherosclerosis and might precede the structural 
changes observed in the arterial wall. 11 ln most stu d-
ies, endothelial function has been assessed invasively 
by determing the vasodilatory response to a choliner-
gie agent, mainly acetylcholine. 12 Noninvasive assess-
ment of endothelial function is now possible by 
evaluating, for instance, the hyperemic response to a 
transient occlusion of the forearm of circulation, by 
applying transcutanously acetylcholine by iontophore-
sis, or by e:\.'Ploring the skin vasodilatation induced by 
local warming. 11 ' 13 
The present investigation was undertaken in an 
attempt to define the contributing role of dylipidemia 
to the pathogenesis of atherosclerosis in metabolic syn-
drome. Two surrogate markers of vasculopathy ( sldn 
microcirculatory endothelial dysfunction and carotid 
IMT) were measured in 2 groups of overweight and 
normoglycemic subjects who were discordant only with 
respect to their lipid values. Both groups were matched 
for age and gender. The dyslipidemia of the 120 cases 
consisted of low HDL-cholesterol (HDL-C) (:::;25 age-
and gender-specific percentile in general population) 
and high triglyceride values (~75 percentile). These 
cases were compared with 120 discordant controls 
exhibiting HDL-C ~50 percentile and triglycerides :::;50 
percentile. 
Methods 
Definition of Cases and Controls 
Individuals age 18 to 70 years were considered as cases 
if they simultaneously had high serum triglycerides 
(~75th age- and gender-specific percentile in gen-
eral population) and low serum HDL-C (:s;25th per-
centile). Control participants were identified if their 
triglyceride values were :::;50 and HDL-C ~50th per-
centile. As inclusion criteria for both groups, the 
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body mass index (BMI) had to be > 25 kg/m2 and 
fasting blood glucose< 6 mmol/L. Antidiabetic treat-
ment and/or known diabetes were considered an 
exclusion criteria. Su bjects were also excluded if 
they had a BMI ~ 35 kg/m2 , were HIV positive, a 
recipient of an organ transplant, or affected with 
familial hypercholesterolemia, if they were heavy 
alcohol drinkers (more than 8 units of alcohol per 
day), or had been under hypolipidemic drug therapy 
within the 4 weeks preceding the lipid evaluation. 
The participants were recruited at the outpatient 
lipid clinic of the university hospital or in the frame 
of health plan survey conducted in several enter-
prises. The institutional ethics committee approved 
the protocol, and informed written consent was 
obtained from each participant. 
Measurements 
A questionnaire was administered to each participant 
to inquire about comorbid conditions such as the use 
of medications and tobacco and alcohol consump-
tion. Height, weight, and waist circumference were 
determined in each subject. Three blood pressure 
measurements were obtained in the sitting position 
using an electronic oscillometric device (Omron/907; 
Omron Manufacturing of America, St. Charles, Ill). 
The average of the second and third systolic and dias-
tolic blood pressure readings was used for analysis. 
Ambulatory blood pressure monitoring was recorded 
every 15 min during the day for a 12-hour period 
using the TM-2420, model 7 (A&D Instruments, 
Abington, Oxon, United Kingdom) device. A blood 
sample was collected after 12 hours of fasting. 
Assessment of a Peripheral 
Atherosclerosis Score and IMT 
The presence of peripheral atherosclerosis was 
assessed using B-mode high resolution imaging of 
both carotid and femoral arteries. The number of ves-
sels containing atherosclerotic plaque(s)-defined by 
an encroachment of the arterial wall into the lumen ~ 
1.2 mm-was assessed as an index of peripheral ath-
erosclerosis score (ATS). The IMT was also evalu-
ated and standardized as proposed by Kastelein at 
al. 9 ln brief, the average IMT was the result of the 
far wall across 3 segments in the left and right carotid 
arteries: carotid bifurcation, common carotid, and 
internai carotid. Validity and reproducibility of the 
carotid measurements using the B-mode ultrasound 
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protocol have been reported elsewhere. 9 The ultra-
sound evaluation was clone by a single operator who 
was not aware of the lipid profile of the participants. 
Endothelial Function 
Microvascular blood flow was studied by laser-Doppler 
flowmetry as described previously. 13 Noninvasive eval-
uation of endothelial function in the forearm skin was 
evaluated in a subgroup of 99 cases and 86 controls by 
determining the skin blood flow response to local heat-
ing (3 7°C and 41 °C) as well as to a transient occlusion 
of arterial circulation (inflation of a conventional arm 
cuff for 3 min at 200 mm Hg). 13 
Clinical Chemistry 
Blood values for glucose, lipid, and high sensitivity 
C-reactive protein (hs-CRP) were assessed in the 
clinical chemistry laboratory of the Lausanne 
University Hospital using standard procedures. 
Case-control Matching Procedure 
Pairs of individuals of same age and gender were 
randomly matched from the 195 affected subjects 
(cases) and the 143 controls. An allowance for a lim-
ited difference in age (maximum, 3 y) was intro-
duced in the matching criteria. ln a first stage, only 
subjects with complete assessment of endothelial 
fonction (99 cases; 86 controls) were eligible for 
matching, and 74 pairs could be formed. ln a second 
stage, all remaining cases and controls were 
matched, leading to the formation of 46 additional 
pairs. Therefore, a total of 120 pairs were available 
for analysis. 
Statistical Analyses 
The comparison of cardiovascular risk factor levels 
between cases and controls was based on paired t 
tests for continuous variables and on chi-square 
tests for categorical variables. The association 
between these risk factors and peripheral athero-
sclerosis-defined as the presence of at least 1 ath-
erosclerotic plaque in the 4 e".rplored arteries-was 
first examined in cases and controls separately using 
univariate logistic regression models. In order to 
determine whether dyslipidemia (cases, but not con-
trols) is a determinant of peripheral atheroscelosis 
independently of other risk factors, a multivariate 
conditional logistic regression model was developed 
with all subjects taken together. Variables significantly 
associated to peripheral atherosclerosis in univariate 
logistic regression, in addition to dyslipidemia (ie, 
case vs control) were tested for inclusion in the mul-
tivariate model using a stepwise backward procedure 
(with statistical significance levels for entry and rejec-
tion set at P < .10 and P < .20, respectively). All sta-
tistical analyses were carried out using the STATA 
software (release 8.1; Stata Corp, College Station, 
Texas). Data are reported as mean ±SEM. 
Results 
Clinical Characteristics of the 
Participants of the Study 
The clinical characteristics of the 120 cases and 120 
controls are described in Table 1. The 2 groups were 
age and gender matched. Mean BMI was similar in 
both groups. \Naist, waist to hip ratio, and office sys-
tolic and diastolic blood pressures were significantly 
higher in the affected individuals compared with the 
controls. The average of daytime blood pressures did 
not show any significant differences between cases 
and controls. Smokers were significantly more 
prevalent in the affected individuals (34% vs 21 % in 
cases vs controls, respectively). 
The laboratory values of the subjects are also 
described in Table 1. The lipid abnormalities were 
significantly more pronounced in cases. The fasting 
blood sugar was 5.3 ± 0.4 mmol/L and 5.4 ± 0.4 
mmol/L in controls and cases, respectively. The 
ultrasensitive C-reactive protein values were signifi-
cantly different in the affected group (2.8 ± 0.22 
mg/L) compared with controls (1.6 ± 0.15 mg/L; P < 
.05). The subjects were then stratified according to 
their hs-CRP values. 14-16 
Evaluation of Peripheral Atherosclerosis, 
IMT, and Endothelial Function 
We first evaluated the presence of atherosclerotic 
plaque(s) in both carotid and femoral artery bifurca-
tions. A site was considered as positive if 1 or more 
plaque were detected in the arterial wall. Plaque was 
defined as an encroachement of the arterial wall into 
the lumen of at least 1.2 mm. The mean of positive 
sites in controls was 0.8 ± 0.15 compared with 1.5 ± 
0.15 in cases (P < .001) (Figure lA). The percentage 
of subjects exhibiting plaques in explored arteries was 
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Table 1. Clinical and Biochemical 
Characteristics of the Participants" 
Controls Cases p 
(n=l20) (n=l20) Value 
Gender 83 M/37 F 83 M/37 F 
Age, y 51 (4 7/55) 51 (47/55) 0.5 
BMI, kg/m 2 28 (26/30) 28 (26/31) .5 
Obesity (330) 25% 35% .09 
\Vaist, cm 93 (89/102) 97 (91/105) .02 
Hip, cm 107 (102/112) 106 (102/111) .8 
WHR 0.89 (0.85/0.92) 0.92 (0.88/0.95) <.001 
Abdominal obesity 35% 50% .02 
(> 102 cm, >88 cm) 
Office SBP, 124 (115/131) 127 (120/135) .007 
mm Hg 
Office DBP, 80 (70/83) 80 (75/86) .02 
mmHg 
Ambulatory SBP, 130 (125/136) 133 (125/145) .13 
mmHg 
Ambulatory DBP, 80 (77/87) 83 (78/88) .07 
mmHg 
Hypertension 12 (10%) 34 (28%) <.001 
treated 
BP;::: 130/85 mm Hg 37% 53% <.001 
BP;::: 140/90 mm Hg 9% 22% <.001 
BP;::: 160/95 mm Hg 2% 4% <.001 
Smokers 21% 34% .04 
HDL-C, mM 1.7 (1.5/1.9) 1 (0.9/1.1) <.001 
TG,mM 0.9 (0.8/1.1) 2.4 (1.9/3.3) <.001 
TC,mM 5.3 (4.7/5.9) 6 (5.3/6.6) <.001 
TC/HDL-C 3.2 (2.6/3.6) 5.3 (4.6/6.2) <.001 
LDL-C, mM 3.1 (2.6/3.7) 3.7 (3.2/4.5) <.001 
NOTES: M =male; F = female; BMI =body mass index; WHR = 
waist-to-hip ratio; SBP = systolic blood pressure; DBP = diastolic 
blood pressure; BP = blood pressure; HDL-C = high-density 
lipoprotein- cholesterol; TG = triglycerides; TC = total choles-
terol; LDL-C = low-density lipoprotein-cholesterol. 
a. Median data with interquartile range (25 and 75) in parentheses. 
much lower in the control group compared with the 
dyslipidemic subjects. In 55% of the controls, we did 
not detect the presence of any plaque in the 4 explored 
arteries, while only 28% of affected individulas were 
considered as free of any atherosclerotic plaque. 
We next evaluated noninvasively by B-mode 
ultrasound the common carotid IMT (Figure 2). The 
IMT were significantly increased in cases compared 
with controls (0.66 ± 0.15 mm vs 0.61±0.15 mm in 
cases vs controls, respectively; P < .05). 
Endothelial fonction was also evaluated as a sur-
rogate marker of atherosclerosis. Table 2 describes 
the clinical and biochemical characteristics of the 
7 4 case-control pairs with complete assessment of 
microvascular endothelial fonction in the forearm 
skin. Results are shown pictorially in Figure 3. The 
peak increase of skin blood flow above the baseline 
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Figure 1. Detection of atherosclerotic plaques in carotid and 
femoral arteries. The presence of atherosclerotic plaque(s) was 
evaluated by B-mode ultrasound in carotid and femoral arteries. 
The presence of an encroachement of the arterial wall into the 
lumen of at least 1.2 mm was considered as a positive site. A, the 
mean of positive site for the presence of plaques was much higher 
in cases compared with contrais (mean ±SEM; ~"''*P < .001). B, 
the prevalence of subjects exhibiting 0, 1, 2, 3, or 4 positive sites 
for the presence of atheroscerotic plaque(s) is inversely correlated 
to the presence or the absence of a dyslipidemia. 
value after the release of a 3-min arterial occlusion 
(reactive hyperemia) was 16% lower in cases ( 141 ± 
6 perfusion unit [PU]) than in controls (168 ± 6, 
P = .003). A comparable difference (15%) was noted 
when this response was quantified as the area under 
curve (AUC) (cases: 21048 ± 1127 PU*sec (PU = 
Perfusion Unit); controls 24314 ± 1150 PU* sec; P = 
.020). Similarly, the vasodilation induced by a sub-
maximal local thermal stimulation (skin temperature 
raised from 34 °C to 3 7°C) was less marked in the 
cases (peak 89 ± 6 PU; AUC 19075 ± 1344 PU'"sec) 
than in the controls (peak 11 ± 6 PU; P = .013; AUC 
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Figure 2. Intima-media thickness (IMT) assessesment in 
cases and contrais. IMT thiclmess was evaluated in the left 
caratid arteria (LCA) and the right carotid arteria (RCA) in 120 
normolipidemic contrais and in 120 dyslipidemic cases. The 
IMTs were significantly increased in the cases compared to 
their discordant contrais (mean ±SEM; H·p < .01). 
Table 2. Clinical Characteristics of the Participants to 
the Endothelial Function Evaluation" 
Gender 
Age, y 
EMI, kg/m2 
Obesity (;?:30) 
\,Yaist, cm 
Hip, cm 
WHR 
Abdominal obesity 
(>102 cm, >88 cm) 
Office SEP, mm Hg 
Office DEP, mm Hg 
Ambulatory SEP, 
mmHg 
Ambulatory DEP, 
mmHg 
Hypertension treated 
EP;::: 130/85 mm Hg 
EP;::: 140/90 mm Hg 
EP;::: 160/95 mm Hg 
Smokers 
HDL-C, 111M 
TG,mM 
TC, mM 
TC/HDL-C 
LDL-C, mNI 
Contrais 
(n = 74) 
49 M/25 F 
51 (47/55) 
29 (26/31) 
35% 
95 (89/103) 
109 (103/114) 
Cases 
(n = 74) 
49 M/25 F 
51 (47/55) 
29 (26/32) 
43% 
100 (92/106) 
108 ( 104/114) 
0.90 (0.85/0.93) 0.91 (0.88/0.95) 
43% 59% 
125 (118/132) 129 (120/135) 
80 (73/85) 81 (75/87) 
130 (125/137) 133 (125/145) 
80 (78/87) 83 (80/88) 
13% 24% 
43% 57% 
12 % 21% 
2.7% 4% 
24% 34% 
1.7 (1.5/1.9) 1.1 (0.9/1.1) 
0.9 (0.8/1.1) 2.4 (1.8/3.2) 
5.5 (4.9/6.2) 6 (5.5/6.6) 
3.3 (2.7/3.7) 5.4 (4.6/6.2) 
3.2 (2.8/3.8) 3.9 (3.3/4.6) 
p 
Value 
1 
.7 
.01 
.2 
.7 
.02 
.02 
.15 
.23 
.5 
.3 
<.001 
.01 
<.001 
<.001 
.01 
<.001 
<.001 
<.001 
<.001 
<.001 
NOTES: M =male; F = female; EMI =body mass index; WHR = 
waist-to-hip ratio; SEP systolic blood pressure; DEP = diastolic 
blood pressure; EP blood pressure; HDL-C = high-density 
lipoprotein- cholesteral; TG = triglycerides; TC = total choles-
teral; LDL-C = low-density lipopratein-cholesteral. 
a. Median data with interquartile range (25 and 75) in parentheses. 
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Figure 3. Endothelium-dependent vasodilatation in the skin 
microcirculation of case and contrai subjects. The time course of 
microvascular skin blood flow was assessed following either a 3-min 
occlusion of arterial inflow into the forearm (reactive hyperemia) or 
a brisk increase of local temperature from 34°C to either 37°C or 
41°C. The reactive hyperemic response consisted in a brisk tran-
sient increase in skin blood flow, followed by a progressive return to 
the baseline value in 60 to 120 seconds. Local heating elicited a 
progressive increase in skin blood flow, reaching a steady value after 
approximately 10 min. Ail responses were quantitated as the ma'(Ï-
mal flow increase (reactive hyperemia: transient peak; local heating: 
steady value between 10 and 11. 5 min) as well as the AU C calcu-
lated for the duration of measurement (reactive hyperemia, 120 
seconds; local heating, 11.5 min). For ease of presentation, ail data 
are normalized to the average value obtained in the control subjects 
and presented as mean ±SEM. *P < .05; *"P < .01 cases compared 
with controls. 
24314 ± 1862 PU*sec; P = .024, approximate relative 
difference 20% for both variables). By contrast, the 
much stronger hyperemia elicited by raising sldn tem-
perature from 34°C to 41°C did not differ between the 
2 groups (peak 356 ± 12 PU in cases vs 360 ± 10 PU 
in controls; P = .8; AUC 121072 ± 4380 PU*sec in 
cases vs 125445 ± 3787 in contrais; P = .6). 
Evaluation of the Risk for Developing 
Atherosclerotic Plaque(s) 
We defined the presence of at least 1 positive site in 
any of the 4 eÀ'Plored by B-mode ultrasound arteries 
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Table 3. Independent Risk Factors 
for Peripheral Atherosclerosis (ie, having at least 1 
atherosclerotic plaque) in the 120 Pairs of Cases and 
Con trois Matched for Age and Gender 
Odds Ratio" p 
Variable (95% CI) Value 
Contrais 1.00 
Cases 4.01 (1.55-10.4) .004 
SBP < 120 1.00 
SBP 120-130 4.91 (l.01-23.8) .048 
SBP > 130 7.88 (l.49-41.5) .015 
PA= 0 (nonsmoker) 1.00 
PA 1-20 2.12 (0.46-9.67) .331 
PA> 20 4.48 (0.94-23.4) .059 
NOTES: CI= confidence interval; SBP = systolic blood pressure; 
PA = pack-year. 
a. The odds ratios are adjusted for the other variables in table 
(multivariate analysis). 
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as a manifestation of asymptomatic atherosclerosis. 
The odds ratios (OR) for developing atherosclerotic 
plaque(s) were first analyzed in an multivariate analy-
sis of the 240 individuals. As shown in Table 3, the 
major contributors for developing peripheral athero-
sclerosis were smoking, systolic blood pressure, and 
the presence of a low HDL-C and high triglyceride 
lipid profile. The ORs for developing atherosclerotic 
plaque were then analyzed in an univariate model in 
cases and controls separately. These data are summa-
rized in Table 4. The likelihood of developing athero-
sclerotic plaque in controls increased with age, with 
the presence of high low-density lipoprotein (LDL)-
cholesterol, with high systolic blood pressure and smok-
ing. Regarding the cases, the likelihood for developing 
atherosclerotic plaque was particularly important with 
aging and smoking. 
Table 4. Odds Ratios for Having at Least 1 Plaque According to Severa! Risk Factors, 
Separately for Cases and Controls Matched for Age and Gender 
Contrais Cases 
n" Rate,% OR 95% CI P Value n" Rate,% OR 95% CI P Value 
Men 77 44.2 1.00 77 74.0 l.00 
\Vomen 36 44.4 1.02 0.46-2.24 .977 36 66.7 0.70 0.30-1.66 .420 
Age 38-49 y 45 28.9 1.00 45 55.6 l.00 
Age 50-54 y 35 57.1 3.28 l.29-8. 31 .012 35 74.3 2.31 0.88-6.03 .087 
Age 55-65 y 33 51.5 2.61 1.02-6.69 .045 33 90.9 8.00 2.13-30.1 .002 
Office SBP < 120 45 33.3 1.00 33 69.7 I.00 
Office SBP 120-130 39 46.2 l. 71 0.71-4.15 .232 31 71.0 l.06 0.36-3. l l .911 
Office SBP > 130 29 58.6 2.83 1.08-7.43 .034 49 73.5 l.20 0.45-3.20 .709 
Office DBP < 75 46 41.3 l.00 46 66.7 1.00 
Office DBP 75-82 34 41.2 0.99 0.40-2.45 .991 34 75.0 1.50 0.51-4.41 .461 
Office DBP > 82 33 51.5 l.51 0.61-3.71 .370 33 72.9 l.35 0.51-3.53 .546 
TC< 5.3 51 37.3 l.00 18 61.l l.00 
TC= 5.3-6.2 39 48.7 l.60 0.69-3. 73 .276 46 69.6 1.45 0.47-4.53 .518 
TC> 6.2 23 52.2 l.84 0.68-4.97 .231 49 77.6 2.20 0.69-7.02 .184 
LDL-C < 3.0 41 34.1 l.00 19 57.9 l.00 
LDL-C = 3.0-3.9 34 41.2 1.35 0.53-3.46 .531 32 69.8 1.60 0.49-5.20 .434 
LDL-C > 3.9 20 65.0 3.58 l.16-1 I.O .026 44 75.0 2.18 0.70-6.80 .179 
Glycemia < 5.0 33 45.5 l.00 20 l.00 
Glycemia = 5.0-5.6 55 41.8 0.86 0.36-2.06 .739 53 0.7 0.65 0.20-2.07 .464 
Glycemia > 5.6 25 48.0 1.11 0.39-3.14 .847 40 l.l 1.15 0.33-4.03 .829 
PA= 0 53 32.1 1.00 37 56.8 1.00 
PA= 1-20 41 48.8 2.02 0.87-4.47 .102 26 76.9 2.54 0.82-7.79 .103 
PA> 20 18 72.2 5.51 1.69-17.9 .005 49 81.6 3.38 1.28-8. 96 .014 
CRP < 1 46 45.5 1.00 26 62.5 l.00 
CRP = 1-3 41 41.0 0.83 0.35-2.00 .685 38 69.4 l.36 0.46-4.05 .577 
CRP > 3 20 47.4 l.08 0.37-3.17 .889 43 73.8 1.69 0.58-6.85 .338 
Total 113 44.2 I.00 113 71.2 3.19 1.84-5.54 <.001 
NOTES: OR= odds ratio; CI= confidence interval; SBP = systolic blood pressure; DBP = diastolic blood pressure; TC= total cholesteral; 
LDL-C = low-density lipoprotein-cholesterol; PA= pack-year; CRP = C-reactive protein. 
"The number of patients in the categories of a given variable may not add up to the total number of cases and contrais because of 
missing values. 
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Discussion 
High blood pressure, smoking, diabetes, and dyslipi-
demia are established risk factors for atherosclero-
sis. The metabolic syndrome includes several of 
these factors and represents an heterogenous dis-
ease where several cardiovascular risk factors occur 
in various degrees and in different combinations in 
a given individual. It is therefore difficult to evaluate 
the contribution of a single proatherogenic risk fac-
tor in individuals with metabolic syndrome. ln an 
attempt to better characterize metabolic syndrome, 
a large multicentric study was recently undertaken 
to evaluate whether the low HDL-C and high 
triglyceride lipid profile observed in metabolic syn-
drome is a sensitive marker of genetic homogeneity 
in subjects with metabolic syndrome. The study was 
named GEMS (Genetie Epidemiology of Metabolic 
Syndrome) and was designed as a family-based study 
to compare 1436 affected subjects with 1672 unaf-
fected individuals. 17 The inclusion criteria to iden-
tify cases and contrais in GEMS were the ones used 
in this present study. Using this simple lipid-based 
criteria, 72% and 88% of the affected participants in 
the age group of 36 to 54 and~ 5 5 years, respectively, 
met the criteria of ATPIII definition for metabolic 
syndrome. 17 ln the present study, cases and contrais 
defined by the GEMS criteria were carefully 
matched for age and gender. The BMI was similar in 
both groups. Among inclusion criteria, a glycemia < 
6 mmol/L was required. Office blood pressures were 
slightly different in both groups. However, the day-
time average ambulatory blood pressures were not 
different between cases and contrais. Thus, these 
cases and contrai subjects represented a quite com-
parable and homogenous group of individuals meet-
ing several criteria of metabolic syndrome, except 
with regard to the lipid profile. This mode of selec-
tion was chosen to better explore the contribution of 
dyslipidemia as part of the metabolic syndrome to 
the development of peripheral atherosclerosis. 
Since the clinical manifestations of atheroscle-
rosis develop often late in life, we used several sur-
rogate markers for the presence of subclinical 
atherosclerosis. 
High-sensitivity CRP is a recognized biomarker 
of chronic inflammation. 15 ln a large prospective 
study, it was shown that CRP was a better predictor 
of the risk of cardiovascular events compared with the 
LDL-C. 14 The predictive values of 11 atherothrom-
botic biomarkers for the occurrence of atherosclerosis 
in the same cohort of 14916 physicians was also 
reported. 16 Out of the 11 biomarkers, the total cho-
lesterol HDL-C ratio and the hs-CRP were the 
strongest independent predictors of development of 
peripheral arterial disease. 16 This has been recently 
challenged as hs-CRP was found to be only a mod-
erate predictor of coronary heart disease. 18 Hs-CRP 
levels were shown, however, to correlate with fasting 
triglycerides and glucose concentrations, obesity, 
and blood pressure. It seems therefore appropriate 
to consider hs-CRP as a biomarker of metabolic syn-
drome. This view is supported by the results of the 
present study: the mean average of hs-CRP levels 
were indeed significantly higher in cases compared 
with contrais. 
ln the present study, we found that subjects with 
the low-HDL and high triglyceride lipid profile had 
significantly increased carotid IMT compared with 
normolipidemic contrais. The number of atheroscle-
rotic plaques was also significantly greater in cases 
than contrais. The variable used to define subclini-
cal atherosclerosis was the presence of at least 1 
positive site in any of the 4 e>..'Plored arteries. ln a 
multivariate analysis, the likelihood for developing 
atherosclerotic plaques was strongly enhanced in 
cases compared with contrais (OR: 4.01; confidence 
interval [CI]: 1.55-10.4; P = .004). ln cases, age 
above 5 5 years was the strongest risk factor for 
developing atherosclerotic plaques (OR: 8,0; CI: 
2.13-30. l; P < .002). In contrais, the prevalence of 
atherosclerotic plaque was much lower and, if pres-
ent, the plaque was associated with higher levels of 
LDL-C, smoking, or high systolic blood pressure. Thus, 
among several criteria of metabolic syndrome, the low 
HDL-C and high triglyceride lipid profile appeared to 
be a strong and independent contributor to periph-
eral atherosclerosis. 
The use of B-mode IMT measurements to inves-
tigate the determinants of atherosclerosis disease 
has been validated in many studies, including the 
Atherosclerosis Risk in Communities Study (ARIC) 
and the Rotterdam Stud)' 10•19·23 Solid evidence doc-
umented the association between carotid IMT and 
coronary heart disease, stroke, claudication, and 
high blood pressure. ln the ARIC study, a 0.2-mm 
increase in carotid IMT was shown to be associated 
with a 28% increase in relative risk for stroke and 
33% increase in relative risk for myocardial infarc-
tion. Eric de Groot and co-authors studied the char-
acteristics of arterial walls of subjects with familial 
hypercholesterolemia (FH) and compared them with 
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those of age-matched nondyslipidemic subjects. 9 In 
children at age 10, the IMTs in FH subjects or their 
controls were similar. However, the progression of 
IMTs varied considerably with age so that, in average, 
the IMT increase observed with age was at least tw:ice 
as large in FH subjects than in controls. As an exam-
ple, a mean common carotid artery IMT of O. 78 mm 
was measured in healthy 76-year-old subjects while 
the same value was already observed at the age of 40 
y in subjects with FH. Considering our data, the aver-
age IMT of 0.61 mm in the controls matched approx-
imately an average age-adjusted IMT for healthy 
45-year-old individuals. 9 On the other hand, the aver-
age IMT of 0.66 mm measured in the cases corre-
sponds approximately to the IMT measured in 
55-year-old normolipidemic individuals. 9 
As a surrogate marker of subclinical atheroscle-
rosis, we also evaluated endothelial fonction in a 
subset of individuals with or without atherogenic 
dyslipidemia. We used a laser Doppler imaging sys-
tem to measure skin blood flow in the forearm. The 
device was established as a highly reproducible tool 
to evaluate in the forearm the postischemic hyper-
emia as well as the vasodilation induced by local 
warming of the skin, responses that are thought to 
be mediated mainly by the endothelium. 13 vVe found 
that the cases have a blunted thermal-induced 
vasodilatation as well as a reduced reactive hyper-
emia compared with age-gender-BMI-matched indi-
viduals with a favorable lipid profile. These data are 
in accordance with the accumulating evidence sug-
gesting that endothelial dysfonction might be an 
early marker for subclin:ical atherosclerosis. 11 Our 
subjects were overweight, and previously published 
data demonstrated that obesity, with or without 
insulin resistance, has no effect per se on endothe-
lial fonction measured in the forearm. 24 So the 
impaired-endothelial vasodilatation observed in our 
cases compared with their discordant controls is most 
likely the result of the low HDL and high triglyc-
eride lipid profile. These results are in agreement 
with a recent observation of R J Biosendial and co-
authors. 25 They studied endothelial fonction in 9 sub-
jects with isolated low HDL-C linked to heterozygote 
carries of the ABCAl mutations. In these individuals, 
they measured an impaired vasodilatory effect of the 
endothelium, which was corrected after a single, rapid 
infusion of apolipoprotein A-I/phosphatidylcholine dises 
(apoA-I/PC). 
Taken together, these data support the conclu-
sion that the low-HDL-C and high triglyceride 
lipid profile is a strong risk factor for developing 
Atherosclerosis and Metabolic Syndrome/ Genoud et al 49 l 
peripheral atherosclerosis. This lipid profile is asso-
ciated with an abnormal endothelial fonction and an 
increase in IMT compared to individuals with high 
HDL-C and low triglycerides levels. Although the 
low HDL-C is frequently associated with hyper-
triglyceridemia, our data extend the potential role of 
HDL particles as potent antiatherogenic agents. 26-28 
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Glucose·lnduced lnsulin Secretion in 
Dyslipidemic and ormolipidemic 
Patients ith Normal Glucose Tolerance 
CHRISTOPHE BiNNERT, PHD1 
MYRIAM GENOUD, MD2 
GÉRALD SEEMATTER, MD1 
Ass1A FEKIRINI, MD
1 
T he metabolic syndrome is highly prevalent in industrialized coun-tries, where it represents a major 
public health burden due to the associ-
ated high risk of diabetes and cardiovas-
cular disorders (1,2). High plasma 
triglyceride and low HDL cholesterol are 
prominent features of this syndrome 
(2,3). Large epidemiological studies have 
shown associations with both insulin re-
sistance and low insulin secretion ( 4). The 
aim of this study was to evaluate whether 
the alterations ofblood lipid, observed in 
the metabolic syndrome, are associated 
with alterations of insulin sensitivity or 
secretion in subjects with normal glucose 
tolerance. Glucose homeostasis was eval-
uated during a two-step hyperglycemic 
clamp in a group of dyslipidemic patients 
and in a group of normolipemic subjects 
of similar age and body weight. Subjects 
were studied after short-term administra-
tion of dexamethasone to evaluate recip-
rocal changes in insulin secretion and 
insulin sensitivity (5-8). 
RESEARCH DESIGN AND 
METHODS- Twenty dyslipidemic 
subjects (13 men and 7 women) with BMI 
>27 kg/m2 but having normal glucose 
tolerance, as documented by a standard 
oral glucose tolerance test (fasting glyce-
mia 94 ± 7 mg/dl, 2-h glycemia 95 ± 17 
mg/dl) (9), were selected for the study. 
VINCENT MüOSER, MD, PHD3 
GÉRARD WAEBER, MD, PHD2 
Luc TAPPY, ~m1 •4 
Theyhadamean(±SD)ageof46.6 ± 7.6 
years, body weight of 85.4 ± 10.3 kg, 
height of 173.2 ± 9.2 cm, BMI of 28.6 ± 
4.1 kg/m2 , waist circumference of 98.9 ± 
11.0 cm, waist-to-hip ratio of 0.91 ± 
0.08, fasting plasma triglyceride concen-
tration of 2.25 ± 0.84 mmol/l, fasting to-
tal plasma cholesterol concentration of 
5.66 ± 1.04 mmol/l, fasting HDL choles-
terol concentration of 1.06 ± 0.11 
mmol/l, and blood pressure of 123 ± 13/ 
78 ± 8 mmHg. Theywere compared with 
a group of 20 normolipemic subjects (18 
men and 2 women) with normal glucose 
tolerance (fasting glycemia 96 ± 7 mg/dl, 
2-h glycemia 95 ± 22 mg/dl) and similar 
age (52.6 ± 6.3 years), body weight 
(91.8 ± 17.2 kg), height (176 ± 10 cm), 
BMI (29.6 ± 3.9), waist circumference 
(99.6 ± 12.2 cm), waist-to-hip ratio 
(0.91 ± 0.07), and blood pressure 
(126 ± 11/80 ± 7 mmHg) but had nor-
mal triglyceride (0.80 ± 0.21 mmol/l), 
total cholesterol (5.03 ± 0.91 mmol/l), 
and HDL cholesterol (1.71 ± 0.27 
mmol/l) concentrations. All subjects were 
recruited from the GEMS (Genetie Epide-
miology of Metabolic Syndrome) project 
study population (10). Fourteen dyslipi-
demic and no normolipemic patients ful-
filled the criteria for the metabolic 
syndrome (2). Six dyslipidemic and three 
normolipemic subjects were receiving 
treatment for high blood pressure, and 
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two dyslipidemic patients were being 
treated with statins. 
Each participant took part in a two-
step hyperglycemic clamp (target glyce-
mia of 135 mg/dl during 60 min and of 
180 mg/dl during the next 60 min) to si-
multaneously evaluate glucose-induced 
insulin secretion and glucose/insulin-
mediated glucose disposa!. Participants 
received 2 mg/day dexamethasone during 
the 2 days preceding the clamp procedure 
and 0.5 mg on the morning of the proce-
dure. [6,6-2H2]glucose (bolus 2 mg/kg, 
continuous infusion 20 µg/kg/min for 60 
min before the clamp, then exogenous 
glucose labeled with 1.25% [6,6-2H2 ] 
glucose [hot infusate approach] [11]) was 
used to calculate whole-body glucose ki-
netics. The results obtained were com-
pared by means of unpaired t tests. 
RIESUl.TS- At their inclusion in the 
study, dyslipidemic and normolipemic 
subjects had similar fasting plasma glu-
cose (94 ± 7 vs. 97 ± 7 mg/dl) and insu-
lin (31.5 ± 4.9 vs. 31.7 ± 7.4 mU/l). 
After administration of dexamethasone 
for 2 days (Table 1), dyslipidemic subjects 
had fasting glucose and insulin concen-
trations that were not significantly differ-
ent from those of nonnolipemic subjects. 
During the clamp procedure, similar rates 
of exogenous glucose infusion were nec-
essary to maintain target glycemia (Table 1). 
However, the rates of exogenous infusion 
divided by steady-state plasma insulin con-
centration were lower in dyslipidemic than 
in normolipemic subjects, indicating im-
paired glucose/insulin-induced glucose 
metabolism. Compared with normoli-
pemic subjects, dyslipidemic subjects had 
41 and 74% higher plasma insulin con-
centrations during the low and high pla-
teaus of glycemia, respectively. Basal 
endogenous glucose production and its 
suppression at both plateaus of glycemia 
were similar in dyslipidemic and normo-
lipemic subjects. 
CONCLUSIONS- This study fo-
cused on dyslipidemic patients free of any 
disorder of glucose homeostasis. Such pa-
1225 
Glncose-induced insulin secretion 
Table 1-Parameters of glucose metabolism duri11g the two-step hyperglycelllic clalllp proce-
dure in dyslipidelllic a11d 1101111olipemic ovenveight subjects with normal glucose tolerance 
Dyslipidemic Normolipemic p 
Il 20 20 
plasma glucose (mg/dl) 
Basal 108.9 :±: 17.6 105.6 :±: 8.3 0.49 
Clamp first plateau 133.6 :±: 3.9 136 :±: 3.4 0.06 
Clamp second plateau 179.1 :±: 5.5 182 :±: 6.7 0.10 
Plasma insulin (mU/l) 
Basal 28.3 :±: 13.9 20.9 :±: 12.3 0.09 
Clamp first plateau 60.1 :±: 28.8 42.6 :±: 25.4 0.05 
Clamp second plateau 157.2 :±: 70.7 90.3 :±: 45.5 0.002 
Glucose infusion rate 
(mg· kg- 1 • min- 1) 
Clamp first plateau 1.08 :±: 0.61 1.25 :±: 0.70 0.43 
Clamp second plateau 3.23 :±: 1.30 2.83 :±: 0.99 0.33 
Glucose infusion rate: insulin 
(mg· l ·kg-!. min-!. mu- 1) 
Clamp first plateau* 0.023 :±: 0.016 0.065 :±: 0.095 0.05 
Clamp second plateaut 0.027 :±: 0.018 0.049 :±: 0.041 0.03 
Endogenous glucose production 
(mg· kg- 1 • min- 1) 
Basal 1.9 :±: 0.4 1.9 :±: 0.6 0.84 
Clamp first plateau 0.7 :±: 0.3 0.5 :±: 0.3 0.08 
Clamp second plateau 0.5 :±: 0.2 0.4 :±: 0.3 0.22 
Data are means ± 1 SD. *Values at the end of each plateau; tvalues averaged during the last 30 min of the 
clamp at each plateau of glycemia. 
tients offer the possibility to investigate 
the contribution of insulin sensitivity 
and/or secretion in the pathogenesis of 
dyslipidemia. Glucose homeostasis was 
evaluated by a two-step hyperglycemic 
clamp after administration of dexametha-
sone, a procedure aimed at decreasing in-
sulin sensitivity with compensatory 
hyperinsulinemia. The rate of exogenous 
glucose infusion divided by plasma insu-
lin concentration was lower in dyslipide-
mic than in normolipemic subjects, 
indicating a lower insulin- and glucose-
induced glucose disposal. Although this 
protocol was not performed without 
dexamethasone administration, these 
results are consistent with some degree 
of insulin resistance in dyslipidemic 
subjects. Dyslipidemic subjects also had 
significant1y higher plasma insulin con-
centration at each plateau of glycemia, 
consistent with impaired insulin sensitiv-
ity, but this also indicates that their glu-
cose-induced insulin secretion was not 
decreased. This hyperinsulinemia cannot 
be attributed to differences in BMI or 
body fat distribution, since dyslipidemic 
and normolipemic patients had similar 
characteristics. Since both groups had 
1226 
similar plasma glucose and insulin con-
centrations before dexamethasone, we 
propose that short-term dexamethasone 
administration offers a way to detect sub-
clinical insulin resistance in dyslipidemic 
patients. 
ln conclusion, our results indicate 
that dyslipidemic, glucose-tolerant pa-
tients have increased glucose-induced 
insulin secretion to compensate for im-
paired insulin sensitivity. We propose 
that these alterations are indicative of in-
sulin resistance in dyslipidemic patients. 
The chronic hyperinsulinemia consecu-
tive to insulin resistance may possibly 
contribute to increase plasma triglyceride 
concentrations by stimulation of hepatic 
de novo lipogenesis and secretion of 
VLDLlipoproteins (12,13). Conversely, it 
is also possible that primary alterations of 
hepatic lipid metabolism, leading to hy-
pertriglyceridemia and low HDL levels 
may in the long-term contribute to the 
development of insulin resistance and hy-
perinsulinemia (14,15). Only prospective 
studies in individuals at risk for the met-
abolic syndrome will provide clarification 
between these two hypotheses. 
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Ambulatory blood pressure monitoring: a mean to stratify 
cardiovascular risk 
Bernard Waebera, Myriam Genoudb, François Feihla, Daniel Hayozc 
and Gérard Waeberb 
Objective Current hypertension guidelines stress the 
importance to assess total cardiovascular risk but do not 
describe precisely how to use ambulatory blood pressures 
in the cardiovascular risk stratification. 
Method We calculated here global cardiovascular risk 
according to 2003 European Society of Hypertension/ 
European Society of Cardiology guidelines in 127 patients 
in whom daytime ambulatory blood pressures were 
recorded and carotid/femoral ultrasonography 
performed. 
Results The presence of ambulatory blood pressures 
~ 135/85 mmHg shifted cardiovascular risk to higher 
categories, as did the presence of hypercholesterolemia 
and, even more so, the presence of atherosclerotic 
plaques. 
Introduction 
The usefulness of ambulatory blood pressure monitoring 
(ABPM) in the diagnosis and the management of 
hypertension is now well recognized [ 1-3]. Blood 
pressures recorded during everyday activities provide a 
better estimate of cardiovascular (CV) risk than blood 
pressure readings obtained conventionally in a medical 
setting [ 4]. Current hypertension guidelines recornrnend 
operational thresholds for ambulatory blood pressure 
readings (ABPs). For instance, The Working Croup on 
Blood Pressure Monitoring of the European Society of 
Hypertension proposes to consider as normal ABPs 
< 135/85 rnmHg during daytime and < 120/70 mmHg 
during night-time [3]. Similar limits were set by experts 
in the USA [2]. 
For many years, management strategies have been based 
on the presence or absence of individual risk factors. 
Typically, this was the case for hypertension. More 
recently, the rationale for a multifactorial CV risk 
assessment approach became apparent [5,6]. The aim 
is, by determining the individual's absolute CV risk, to 
better target the therapeutic interventions and, thereby, 
to render them more beneficial and more cost-effective. 
The latest hypertension guidelines made available by the 
European Society of Hypertension and the European 
Society of Cardiology have adopted the global risk 
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Conclusion Further studies are, however, needed to 
define the position of ambulatory blood pressures in the 
assessment of cardiovascular risk. B/ood Press Monit 
12:263-265 © 2007 Lippincott Williams & Wilkins. 
Blood Pressure Monitoring 2007, 12:263-265 
Keywords: ambulatory blood pressure monitoring, cardiovascular risk, 
carotid ultrasonography, hypercholesterolemia, hypertension 
aDivision of Clinical Pathophysiology, bDepartment of Medicine and cDivision of 
Angiology, University Hospital, Lausanne, Switzerland 
Correspondence Io Professor Bernard Waeber, MD, Division of Clinical 
Pathophysiology, CHUV, University Hospital, MP14/214, CH-1011 Lausanne, 
Switzerland 
Tel: +41 21 314 07 60; fax: +41 21 314 25 18; 
e-mail: Bernard. Waeber@chuv.ch 
Received 2 November 2006 Revised 16 November 2006 
Accepted 17 November 2006 
assessment approach [1]. According to these recornmen-
dations, the global CV risk of a given individual can be 
calculated by taking into account various pararneters, 
including the level of blood pressure perse, the presence 
or absence of additional risk factors, target organ damage 
or associated clinical conditions. This study was under-
taken to assess how global CV risk would be influenced by 
using ABPs in its calculation. The study was perforrned by 
giving to elevated daytime ABPs the same potential 
adverse impact as the presence of either a CV risk factor 
or a target organ damage. 
Participants and methods 
A total of 127 participants [91 men, aged 49. 7 ± 6.1 years 
(mean ± SD), and 36 wornen, aged 50.4 ± 5.7 years] were 
included. They were al! participants to an international 
study designed to explore the genetic basis of the 
metabolic syndrome and its constituent phenotypes [7]. 
They were selected for this analysis as each of them 
underwent a daytime ABPM and an ultrasonographic 
examination of carotid and femoral arteries. Blood 
samples for measurement of fasting blood glucose and 
lipid concentrations were also obtained from all these 
participants. The study protocol was approved by our 
institutional ethics cornmittee and an informed written 
consent was obtained from each participant. 
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
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Clinic BPs were measured in the sitting position by an 
experienced nurse using an electronic oscillometric 
device (OMRON 907, OMRON Healthcare Europe, 
Hoofddrop, The Netherlands). Three readings were 
taken at 2-min intervals and the average of the last two 
was used for analysis. ABPs was recorded every 15 min 
during daytime over a 12-h period using the TM-2420 
Boso (Bosch and Sohn, Jungingen, Germany) device. The 
presence of peripheral atherosclerosis was assessed using 
a B-mode high-resolution imaging of both carotid and 
femoral arteries. The ultrasound evaluation was per-
formed by a single operator. An atherosclerotic plaque was 
defined as the presence of an encroachment of the 
arterial wall into the lumen ;:::: 1.2 mm. 
The global CV risk of the 127 participants was estimated 
using the stratification proposed by the 2003 European 
Society of Hypertension/European Society of Cardiology 
(ESH/ESC) guidelines [ l]. Beyond the levels of clinic 
systolic and diastolic blood pressure the following 
parameters were taken into account; total cholesterol as 
a risk factor if > 6.5 mmol/I (mode! 1); daytime ABPs 
;:::: 135/85 mmHg considered as a risk factor (mode! 2); 
presence of atherosclerotic plaque(s) as a target organ 
damage (mode! 3); daytime ABPs ;:::: 135/85 mmHg as a 
determinant of CV risk, assumed to have the same 
importance as the presence of target organ damage 
(mode! 4). According to the 2003 ESH/ESC guidelines, 
there exists four risk categories indicating an approxima te 
absolu te 10-year risk of CV disease of either Jess than 15% 
(low added risk), 15-20% (moderate added risk), 20-30% 
(high added risk) or above 30% (very high added risk). 
Results 
Table 1 shows the number of patients in each category of 
CV risk according to the different models used for 
stratification. 
Table 1 Number of patients in each category of global 
cardiovascular (CV) risk according to the different models used 
for stratification 
CV risk 
Stratification based on Average Low Moderate High 
(a) Clinic BPs 97 28 2 0 
(b) Clinic BPs+ 
Total cholesterol 80 34 13 0 
>6.5 mmol/I (mode! 1) 
Daytime ABPs 67 33 27 0 
;::> 135/85 mm Hg" 
(model 2) 
(c) Clinic BPs + 
Atherosclerosis (model 3) 43 9 35 40 
Daytime ABPs ;::> 135/ 67 3 14 43 
85 mmHgb (model 4) 
"ln attributing to increased ABPs the same impact on CV risk as any independent 
CV risk factor. bln attributing to increased ABPs the same impact on CV risk as 
the presence of any targe! organ damage, BP, blood pressure; ABP, ambulatory 
blood pressure, 
Taking into account only clinic BPs most participants 
exhibited an average or a low-added risk. A modest but 
clear-cut shift to higher risk categories was observed 
when the presence of hypercholesterolemia was included 
in the risk stratification (mode! 1). 
A similar shift to higher-risk categories was observed by 
considering high daytime ABPs as an independent CV 
risk factor (mode! 2). The adverse impact of high ABPs 
appeared more important than that of hypercholester-
olemia. Indeed a greater number of participants was 
present in the moderate added risk category when using 
high ABPs (11 = 27) than high cholesterol levels for risk 
stratification (Il= 13). Notably, no patient was found at 
high risk regardless of the mode! used for stratification. 
Taking atherosclerosis as a marker of target organ damage 
(mode! 3) increased markedly the risk status. A large 
number of participants (11 = 40) showed a high-added risk 
when including this parameter in the global risk calculation. 
\Vhen high daytime ABPs were assumed to be a Joad over 
al! CV risk for the same degree as the presence of 
atherosclerosis (mode! 4), there was also a major shift of 
the risk distribution to higher categories. This was 
manifested by the large number of participants (11 = 43) 
included in the high-added risk class. 
Discussion 
ABPM has proven very useful in the evaluation of 
hypertensive patients as it better reflects CV risk than 
BPs measured conventionally by doctors [ 4]. The 
indication of ABPM in patients with suspected 'white-
coat' hypertension (also called isolated office hyperten-
sion) is now widely accepted [1,2] and a recent analysis 
has confirmed the cost-effectiveness of this technique 
[8]. The interpretation of blood pressure profiles 
recorded away from the medical environment is, however, 
still debated. A major issue is whether it is justified or not 
to keep a patient untreated if he or she repeatedly 
exhibits high office BPs, but normal BPs during everyday 
activities. Thus, 'white-coat' hypertension may not be 
totally innocent: (i) it seems to be linked with an 
increased probability to develop sustained hypertension, 
regardless of the setting of BP measurement; and (ii) it 
might be associated with an heightened risk of suffering 
target organ damage compared with individuals having 
normal conventional BPs [9]. 
Today global risk assessment is strongly recommended to 
avoid overtreatment in patients who have a low CV risk 
and, conversely, undertreatment in patients with high CV 
risk [10]. lt appears therefore attractive to include ABPM 
in the stratification of CV risk. This was performed in this 
study in participants to a survey in which a number of 
investigations were performed, including ABPM, lipid 
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
profile determination and examination of carotid and 
femoral arteries by ultrasonography. This allowed the 
calculation of global CV risk of these participants, using 
the framework proposed in the 2003 ESH/ESC guidelines 
[1]. Different models were tested for incorporating ABPs 
into this framework, by assigning it the same loading on 
global risk assessment as either hypercholesterolemia or 
presence of target organ damage (atherosclerotic plaques). 
The confirmation of hypertension by ABPM shifted CV risk 
to higher categories. This was particularly true when ABPs 
were given the same importance as target organ damage. 
Notably, there was no high-risk patient by taking into 
account only clinic BPs and total cholesterol values. Similar 
observations were made by attributing to high ABPs the 
same deleterious impact as hypercholesterolemia. In 
contrast, the estimation of risk based on clinic BPs and 
the presence of either atherosclerotic plaques (without 
consideration of ABPs) or high ABPs (without consideration 
of atherosclerotic plaques) gave comparable results, each 
attributing approximately one-third of the studied partici-
pants to the high risk class. 
These observations support the view that abnormally 
elevated daytime ABPs contribute importantly to global 
CV risk. The value of ABPM in stratifying CV risk, 
however, remains to be verified in prospective trials. 
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